FindTrial
Sign In

Impact of serum AMH level on treatment of PCOS patients with Clomiphene citrate

Correlation of basal Serum AMH values of PCOS patients to ovarian response following stimulation with ovulation induction agent Clomiphene citrate

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041956
Enrollment
50
Registered
2022-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R688- Other general symptoms and signs

Interventions

Intervention1: clomiphene citrate as ovulation induction agent: RECRUITED PATIENTS WOULD RECEIVE CLOMIPHENE CITRATE FOR 5DAYS STARTING DAY2/3 OF MENSTRUAL CYCLE STARTING DOSE-50MG WITH SUBSEQUENT ESCA

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PCOS PATIENTS VISITING THE INFERTILITY CLINIC FOR MANAGEMENT OF INFERTILITY

Exclusion criteria

Exclusion criteria: HYPOTHYROIDSM,HYPERPROLACTINEMIA,DIABETES,H/O ESTABLISHED ENDOMETRIOSIS,H/O PELVIC TUBERCULOSIS,PATIENTS UNWILLING TO PARTICIPATE IN THE STUDY

Design outcomes

Primary

MeasureTime frame
NUMBER OF PRE OVULATORY FOLLICLESTimepoint: DAY 15 AND DAY 18 OF MENSTRUAL CYCLE OF THE PATIENT IN WHICH SHE RECEIVES TREATMENT WITH CLOMIPHENE CITRATE—

Secondary

MeasureTime frame
clinical pregnancy rate,ongoing pregnancy rate,biochemical pregnancy rate,miscarriage rateTimepoint: 6weeks—

Countries

India

Contacts

Public ContactPLABANI SARKAR

PGIMER ,CHANDIGARH

surivanita@yahoo.co.in9914209346

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026